Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HC-1119 in Metastatic Castration-Resistant Prostate Cancer
NCT03774056Phase 1Completed
- Sponsor
- Hinova Pharmaceuticals Inc.
- Start
- Feb 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deutenzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hinova Pharmaceuticals Inc. Primary endpoints: Dose-limiting toxicities at 12 weeks and Number of patients with adverse events at 12 weeks. Started Feb 2017; status: completed.
02
Drugs
deutenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03774056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03774056.